Literature DB >> 30260940

Notes from the Field: Blastomycosis Cases Occurring Outside of Regions with Known Endemicity - New York, 2007-2017.

Robert McDonald, Elizabeth Dufort, Brendan R Jackson, Ellis H Tobin, Alexandra Newman, Kaitlin Benedict, Debra Blog.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 30260940      PMCID: PMC6188125          DOI: 10.15585/mmwr.mm6738a8

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


× No keyword cloud information.
In October 2017, the New York State Department of Health was alerted by Albany-area infectious disease physicians about local cases of blastomycosis, including multiple severe infections, in the state health department’s Capital District, an area where Blastomyces spp. fungi are not considered endemic. The majority of patients reported no travel to regions where blastomycosis is known to be endemic, prompting a state investigation of the disease. Blastomycosis is reportable in only five states (Arkansas, Louisiana, Michigan, Minnesota, and Wisconsin); it is not reportable in New York. To evaluate New York blastomycosis trends, statewide health care data were reviewed for the period 2007–June 2017, and incidence in one county in the Capital District was found to be particularly high. Although not a reportable disease, as an emerging infectious disease in New York, suspected blastomycosis should be reported to local health departments where patients reside. Blastomycosis is an uncommon and underdiagnosed disease caused by inhalation of Blastomyces spp. fungi, which grow in moist soil and organic matter. Based on reports of animal and human cases, Blastomyces spp. are thought to be endemic in areas of North America along the Great Lakes and the Mississippi, Ohio, and Saint Lawrence River valleys (). Unlike the similar fungal diseases coccidioidomycosis and histoplasmosis, a skin test has not been available to assess geographic distribution of exposure. Data regarding blastomycosis in New York are limited, with reports of canine infections suggesting endemicity along the Saint Lawrence River on the New York-Canada border (). Outdoor exposures and proximity to waterways have been associated with the disease; however, little about its ecology and epidemiology is known. Pneumonia is the most common manifestation of blastomycosis. Approximately half of blastomycosis infections can be asymptomatic; however, infection can lead to severe and fatal disease, often from respiratory failure. Disseminated infection can involve any organ, often including cutaneous abscesses and osteomyelitis, and is frequently accompanied by fever, weight loss, and night sweats. Blastomycosis is treated with antifungal medications, typically itraconazole or another azole for mild or moderate disease and lipid formulations of amphotericin B for severe disease. Delays in diagnosis of more than 1 month have been observed in >40% of patients (), suggesting that a diagnosis of blastomycosis is often not considered until after other treatments have failed. Blastomycosis diagnosis can be confirmed by fungal culture, with the optimal specimen source depending on the type of infection. Pulmonary blastomycosis can be detected on sputum and lower respiratory cultures. Blastomyces spp. also can be identified on histopathology. Polymerase chain reaction can be used to confirm culture or histopathologic identification and on blood to detect disseminated disease. Blastomyces spp. antigen and antibody tests can aid in diagnosis, although clinicians should be aware that these tests have limited sensitivity and can cross-react with Histoplasma capsulatum and other fungi (). A 2012 epidemiologic and ecologic review found that in Illinois and Wisconsin, where blastomycosis is considered endemic, the range of annual incidence was 0.4–2.6 cases per 100,000 population (). To evaluate New York blastomycosis trends, statewide hospital, emergency department, and hospital-associated outpatient International Classification of Diseases (ICD) codes from the Statewide Planning and Research Cooperative System data set were reviewed for the period 2007–June 2017. During 2007–2015, blastomycosis ICD codes were identified for an annual mean of 24 (range = 17–30) patients (average annual incidence = 0.1 cases per 100,000 population). In 2016, blastomycosis ICD codes were identified for 59 patients (incidence = 0.2 cases per 100,000). Preliminary data from the first 6 months of 2017 include 25 patients, above the previous annual mean. Incidence in one county along the Mohawk River in the Capital District was particularly high, with a mean of 2.2 cases per 100,000 (range = 0–6.1) during 2007–2016. Travel and exposure information were not available. Although ICD codes likely involve misclassification, identifying only a small proportion of infections, these data, combined with case reports, indicate that blastomycosis might be endemic in eastern upstate New York. These findings, along with reported cases of blastomycosis in Texas, Kansas, Nebraska (), and Vermont (), highlight limitations of the existing blastomycosis endemic map* and the need for better data. Active blastomycosis case finding is under way in New York, as is investigation of passively reported cases to assess common exposures, better characterize risk factors, and evaluate a possible common source associated with the high incidence in the county along the Mohawk River. Although blastomycosis is not currently a reportable disease, health care providers and health care facilities should report suspected cases as an emerging infectious disease in New York to local health departments where patients reside. To prevent delays in diagnosis, which can lead to more severe illness and death, clinicians and laboratorians should be aware that blastomycosis can be acquired in areas outside of regions where the disease is considered endemic and to consider the diagnosis in patients with compatible signs and symptoms.
  4 in total

Review 1.  Clinical and laboratory update on blastomycosis.

Authors:  Michael Saccente; Gail L Woods
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

2.  Pulmonary blastomycosis: a new endemic area in New York state.

Authors:  Nitipong Permpalung; Quanhathai Kaewpoowat; Kunatum Prasidthrathsint; Daych Chongnarungsin; Charles L Hyman
Journal:  Mycoses       Date:  2013-03-18       Impact factor: 4.377

Review 3.  Blastomycosis: new insights into diagnosis, prevention, and treatment.

Authors:  James A McKinnell; Peter G Pappas
Journal:  Clin Chest Med       Date:  2009-06       Impact factor: 2.878

Review 4.  Clinical Manifestations and Treatment of Blastomycosis.

Authors:  Joseph A McBride; Gregory M Gauthier; Bruce S Klein
Journal:  Clin Chest Med       Date:  2017-06-12       Impact factor: 4.967

  4 in total
  9 in total

1.  Disseminated blastomycosis presenting as a retro-orbital mass.

Authors:  Shannon Murawski; Michael Farrell; Fernanda Cordeiro-Rudnisky; Richard Blinkhorn
Journal:  BMJ Case Rep       Date:  2019-07-18

2.  Analysis and modeling of Blastomyces dermatitidis environmental prevalence in Minnesota using soil collected to compare basal and outbreak levels.

Authors:  Katrina M Jackson; Keith C Pelletier; Joni Scheftel; Joshua D Kerkaert; Serina L Robinson; Tami McDonald; Jeff B Bender; Joseph F Knight; Malia Ireland; Kirsten Nielsen
Journal:  Appl Environ Microbiol       Date:  2020-12-18       Impact factor: 4.792

3.  Development of a Duplex Real-Time PCR Assay for the Differentiation of Blastomyces dermatitidis and Blastomyces gilchristii and a Retrospective Analysis of Culture and Primary Specimens from Blastomycosis Cases from New York (2005 to 2019).

Authors:  Mitchell Kaplan; YanChun Zhu; Julianne V Kus; Lisa McTaggart; Vishnu Chaturvedi; Sudha Chaturvedi
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

Review 4.  Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens.

Authors:  Daniel Z P Friedman; Ilan S Schwartz
Journal:  J Fungi (Basel)       Date:  2019-07-20

5.  Close encounters of three kinds: Case-based report of endemic mycoses in the environs of New York city.

Authors:  Ravi Manglani; Helena Tomac Pavosevic; Liying Han; Oleg Epelbaum
Journal:  Respir Med Case Rep       Date:  2020-05-30

Review 6.  Blastomycosis Surveillance in 5 States, United States, 1987-2018.

Authors:  Kaitlin Benedict; Suzanne Gibbons-Burgener; Anna Kocharian; Malia Ireland; Laura Rothfeldt; Natalie Christophe; Kimberly Signs; Brendan R Jackson
Journal:  Emerg Infect Dis       Date:  2021-04       Impact factor: 6.883

7.  Unique Oral Presentations of Deep Fungal Infections: A Report of Four Cases.

Authors:  Vimi S Mutalik; Caroline Bissonnette; John R Kalmar; Kristin K McNamara
Journal:  Head Neck Pathol       Date:  2020-09-05

Review 8.  Re-drawing the Maps for Endemic Mycoses.

Authors:  Nida Ashraf; Ryan C Kubat; Victoria Poplin; Antoine A Adenis; David W Denning; Laura Wright; Orion McCotter; Ilan S Schwartz; Brendan R Jackson; Tom Chiller; Nathan C Bahr
Journal:  Mycopathologia       Date:  2020-02-10       Impact factor: 2.574

9.  Safety Evaluation of an Alpha-Emitter Bismuth-213 Labeled Antibody to (1→3)-β-Glucan in Healthy Dogs as a Prelude for a Trial in Companion Dogs with Invasive Fungal Infections.

Authors:  Muath Helal; Kevin J H Allen; Hilary Burgess; Rubin Jiao; Mackenzie E Malo; Matthew Hutcheson; Ekaterina Dadachova; Elisabeth Snead
Journal:  Molecules       Date:  2020-08-08       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.